Cardiac Marker Testing Market, By Disease, By Biomarker Type, By Product, By End Use, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Description

Cardiac Marker Testing Market size was valued at US$ 5,302.18 Million in 2025, expanding at a CAGR of 10.22% from 2026 to 2033.

Cardiac markers help in assessing and managing patients suspected of acute coronary syndrome (ACS). Common tests include Troponin I and T, HDCRP, myoglobin, and CK-MB. These markers-hormones, enzymes, and proteins-are released into the blood when the heart is stressed or damaged. Doctors use these tests to monitor blood changes and evaluate the severity of a heart attack.

The cardiac marker testing market comprises diagnostic tests that detect biomarkers linked to cardiovascular diseases, such as troponins, creatine kinase-MB, and B-type natriuretic peptides. These tests play a crucial role in the early detection, risk evaluation, and management of heart conditions like myocardial infarction and heart failure. For instance, in 2026, a report by Cancer.org stated that about 44% of the estimated 626,000 cancer deaths in the United States are considered potentially preventable because they are linked to modifiable risk factors such as smoking, excess body weight, and physical inactivity. Screening and early detection programs can further help prevent thousands of additional cancer deaths each year by finding cancers early, when treatment is more likely to be successful.

Cardiac Marker Testing Market- Market Dynamics

Increasing Incidence Of Cardiovascular Diseases To Drive Market Demand

The global incidence of cardiovascular diseases (CVDs) is rising steadily. Heart-related conditions like heart attacks, strokes, and heart failure are becoming more common. This growing prevalence drives the demand for early diagnosis and effective monitoring. The World Health Organization (WHO) confirms that cardiovascular diseases (CVDs) are the leading global cause of death, causing around 17.9 million deaths annually. Cardiac marker tests like troponin, CK-MB, and myoglobin are crucial for early detection, diagnosis, and monitoring of acute coronary events. For instance, in July 2025, according to the WHO, cardiovascular diseases (CVDs) were the leading global cause of death in 2021, responsible for an estimated 17.9 million deaths, or 32% of all deaths, mostly from heart attacks and strokes. Over 75 % of these deaths occurred in low- and middle-income countries, highlighting significant global health disparities. Therefore, the high prevalence and mortality of cardiovascular diseases state the need for cardiac marker tests for early detection and management.

Cardiac Marker Testing Market- Segmentation Analysis:

The Global Cardiac Marker Testing Market is segmented on the basis of Disease, Biomarker Type, Product, End Use, and Region.

The cardiac marker testing market, by disease, includes myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and ischemia. Myocardial infarction leads the market due to the need for early detection and accurate diagnosis. Routine use of cardiac marker tests for monitoring and guiding treatment further strengthens its position. In 2025, Becton, Dickinson and Company (BD) advanced cardiac diagnostic tools with its BD Vacutainer Troponin I Ultra test, designed for rapid troponin detection supporting acute myocardial infarction diagnosis in point-of-care environments. Therefore, the growing prevalence of cardiovascular diseases and ongoing innovations in diagnostic tools continue to drive the demand for cardiac marker testing in managing myocardial infarction effectively.

The Reagents & Kits segment is experiencing significant growth due to the increasing demand for sensitive and specific testing solutions in clinical laboratories, providing accurate detection of cardiac biomarkers and enabling reliable diagnosis and monitoring of cardiovascular conditions. For instance, in Dec 2025, a report by NIH Gov. stated the scoping review identified 145 records related to point-of-care (PoC) diagnostic devices in India's primary healthcare system, of which 9 studies were included after detailed screening, reflecting the focused growth in evidence on PoC use. A study using the AideSmart! The PoC platform reported a 91.6% antenatal screening completion rate in rural women, with mobile health clinics proving cost- and time-efficient for community NCD screening. Therefore, increasing use of reagents and kits underscores their key role in accurate diagnostics and accessible health screening.

Cardiac Marker Testing Market- Geographical Insights

Geographically, the market is shaped by differences in healthcare infrastructure, income levels, government initiatives, and regional disease burden, with North America has maintained a significant market presence, while the Asia-Pacific region is projected to expand rapidly. For instance, in September 2025, according to the Atate.gov, outlining plans to negotiate multi-year bilateral health agreements with partner countries-covering 100 % of frontline healthcare worker funding and essential health commodities during the agreement period and shifting long-term responsibilities to recipient nations. The strategy seeks to establish bilateral agreements with most U.S. aid recipients by early 2026, replacing open-ended aid with co-investment models and enhanced global outbreak surveillance.

The Asia-Pacific market is projected to achieve significant revenue growth over the forecast period, driven by a rising incidence of heart diseases and the need for accurate diagnostic methods. Growing awareness of early diagnosis and treatment is boosting demand for cardiac marker tests. Additionally, increasing healthcare spending and expanding infrastructure, including new hospitals and diagnostic centers, are supporting market growth. For example, on 06 January 2023, Pathkind Labs, in collaboration with Roche Diagnostics, announced the launch of a new cardiac biomarker test, NTProBNP, designed to detect heart failure and support the management of Type 2 Diabetes (T2DM). Therefore, rising disease prevalence, awareness, infrastructure, and innovative diagnostics are driving Asia-Pacific market growth.

Europe Cardiac Marker Testing Market- Country Insights

Europe maintains a steady position in the cardiac marker testing market, supported by the rising incidence of heart diseases, increasing healthcare expenditure, and growing demand for point-of-care testing devices. The region's well-established healthcare infrastructure enables the adoption of advanced diagnostic technologies, contributing to overall market growth. For instance, in 2025, bioMerieux continued expanding its cardiac biomarker diagnostic solutions used in acute care settings, supporting rapid detection of myocardial injury and aligning with the growing need for effective diagnostics amid rising cardiovascular disease incidence. Therefore, the rising burden of cardiovascular diseases, along with strong healthcare infrastructure and continuous diagnostic advancements, is driving sustained growth of the cardiac marker testing market in Europe.

Cardiac Marker Testing Market- Competitive Landscape:

The global cardiac marker testing market is fragmented, with several large and medium-sized players accounting for the majority of market revenue. Major players such as Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, Danaher, and Abbott are deploying various strategies, including mergers & acquisitions, strategic agreements, and new product developments to enhance their market presence. In January 2025, Roche announced that its Roche Digital Pathology Dx whole slide imaging system received approval from the U.S. Food and Drug Administration (FDA) for use with the VENTANA DP 600 slide scanner.This approval strengthens the company's digital pathology capabilities and supports enhanced diagnostic accuracy and workflow efficiency in clinical laboratories. Therefore, ongoing strategic initiatives and regulatory approvals by key players are expected to strengthen innovation and drive competitive growth in the cardiac marker testing market.

Recent Developments:

For instance, in 2025, Siemens Healthcare GmbH advanced its cardiac diagnostics portfolio with the Atellica IM High-Sensitivity Troponin I (TnIH) assay, which enables rapid detection of myocardial infarction and also provides prognostic insights for future cardiac events, enhancing early diagnosis and risk stratification in patients with suspected acute coronary syndromes.

For instance, on 03 January 2025, Abbott collaborated with healthcare providers through its point-of-care network following U.S. FDA clearance of the i-STAT high-sensitivity troponin-I (hs-TnI) cartridge, enabling rapid bedside assessment of patients with suspected myocardial infarction and strengthening clinical partnerships for improved cardiac diagnostics and patient management.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

Abbott Laboratories

bioMerieux SA

Danaher Corporation

Fujirebio

F. Hoffmann-La Roche Ltd.

Siemens Healthineers AG

Beckman Coulter, Inc.

QuidelOrtho

Randox Laboratories Ltd.

Tosoh Corporation

Mindray Medical International Limited

Others

GLOBAL CARDIAC MARKER TESTING MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033

Ischemia
Atherosclerosis
Acute Coronary Syndrome
Congestive Heart Failure
Myocardial Infarction

GLOBAL CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2020 - 2033

Myoglobin
High-Sensitivity C-Reactive Protein (HSCRP)
Troponin I and T
Natriuretic Peptide (BNP and NT-proBNP)
Creatine Kinase-MB (CK-MB)
Others

GLOBAL CARDIAC MARKER TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033

Instruments
Reagents & Kits

GLOBAL CARDIAC MARKER TESTING MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033

Point-of-Care Testing Facilities
Academic Institutes
Laboratory Testing Facilities

GLOBAL CARDIAC MARKER TESTING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV6292

1. Cardiac Marker Testing Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Cardiac Marker Testing Market Snippet by Disease
- 2.1.2. Cardiac Marker Testing Market Snippet by Biomarker Type
- 2.1.3. Cardiac Marker Testing Market Snippet by Product
- 2.1.4. Cardiac Marker Testing Market Snippet by End Use
- 2.1.5. Cardiac Marker Testing Market Snippet by Country
- 2.1.6. Cardiac Marker Testing Market Snippet by Region
2.2. Competitive Insights

3. Cardiac Marker Testing Key Market Trends

3.1. Cardiac Marker Testing Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Cardiac Marker Testing Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Cardiac Marker Testing Market Opportunities
3.4. Cardiac Marker Testing Market Future Trends

4. Cardiac Marker Testing Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Cardiac Marker Testing Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Cardiac Marker Testing Market Landscape

6.1. Cardiac Marker Testing Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Cardiac Marker Testing Market - By Disease

7.1. Overview
- 7.1.1. Segment Share Analysis, By Disease, 2025 (%)
- 7.1.2. Ischemia
- 7.1.3. Atherosclerosis
- 7.1.4. Acute Coronary Syndrome
- 7.1.5. Congestive Heart Failure
- 7.1.6. Myocardial Infarction

8. Cardiac Marker Testing Market - By Biomarker Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Biomarker Type, 2025 & 2033 (%)
- 8.1.2. Myoglobin
- 8.1.3. High-Sensitivity C-Reactive Protein (HSCRP)
- 8.1.4. Troponin I and T
- 8.1.5. Natriuretic Peptide (BNP and NT-proBNP)
- 8.1.6. Creatine Kinase-MB (CK-MB)
- 8.1.7. Others

9. Cardiac Marker Testing Market - By Product

9.1. Overview
- 9.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
- 9.1.2. Instruments
- 9.1.3. Reagents & Kits

10. Cardiac Marker Testing Market - By End Use

10.1. Overview
- 10.1.1. Segment Share Analysis, By Biomarker Type, 2025 & 2033 (%)
- 10.1.2. Point-of-Care Testing Facilities
- 10.1.3. Academic Institutes
- 10.1.4. Laboratory Testing Facilities

11. Cardiac Marker Testing Market - By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Cardiac Marker Testing Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Cardiac Marker Testing Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Cardiac Marker Testing Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Cardiac Marker Testing Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Cardiac Marker Testing Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Cardiac Marker Testing Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Abbott Laboratories
- 12.2.2. bioMerieux SA
- 12.2.3. Danaher Corporation
- 12.2.4. Fujirebio
- 12.2.5. F. Hoffmann-La Roche Ltd.
- 12.2.6. Siemens Healthineers AG
- 12.2.7. Beckman Coulter, Inc.
- 12.2.8. QuidelOrtho
- 12.2.9. Randox Laboratories Ltd.
- 12.2.10. Tosoh Corporation
- 12.2.11. Mindray Medical International Limited
- 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us